Kornimate/medical-research-clean huggingface dataset:
does using a 5 mm telescope in laparoscopic cholecystectomy reduce the incidence of trocar site hernia?

Conditions: Cholelithiasis

Summary: 10 mm telescope is generally used in laparoscopic cholecystectomy surgery. the use of a 10 mm telescope, although rare, causes the development of a trocar site hernia. i̇nvestigators thought that the incidence of trocar site hernia would decrease by using a 5 mm trocar, and investigators planned a study.

10 mm telescope is generally used in laparoscopic cholecystectomy surgery. the use of a 10 mm telescope, although rare, causes the development of a trocar site hernia. investigators thought that the incidence of trocar site hernia would decrease by using a 5 mm trocar, and investigators planned a study. elective laparoscopic with a diagnosis of symptomatic cholelithiasis patients hospitalized in mogadishu-somalia recep tayyip erdoğan training and research hospital and konya training and research hospital general surgery clinic for cholecystectomy operation will be included in the study and randomized into two groups. in the first group, a 10 mm telescope will be used, and in the second group, a 5 mm telescope will be used. patients will be followed up for a total of 3 years in 6-month periods for the development of trocar site hernia.

Eligibility criteria:
inclusion criteria: * patients with symptomatic gallstones above 18 years of age exclusion criteria: * those with a history of abdominal surgery, * open cholecystectomy, * patients who develop cholecystectomy complications, * those with decompensated systemic disease, * patients who do not want to participate in the study
effectiveness of urethral stent irrigation in preventing surgical site infections in adolescents with hypospadias

Conditions: Hypospadias

Summary: this prospective, cluster-randomized, crossover, two-arm controlled clinical trial aims to determine whether urethral stent tube irrigation, combined with urinary catheter drainage, prevents postoperative wound infections compared to urinary catheter drainage alone in adolescents with hypospadias.

hypospadias is one of the most common genital developmental malformations in pediatric patients, with a prevalence of approximately 0.5%. the primary manifestations of hypospadias include an ectopic urethral opening, penile recurvature, and abnormal distribution of the prepuce. currently, urethroplasty is the only treatment for hypospadias, with surgery recommended within the first three years of life. however, due to economic, cultural, and social factors, many children miss the optimal age for surgery and require initial or re-repair surgery during puberty. additionally, some children who underwent hypospadias repair before puberty develop penile recurvature and other complications during adolescence, necessitating reoperation. physiological changes during puberty, such as penile growth, pubic hair development, increased skin appendages, secretions, and frequency of erections, increase the risk of wound infection and poor healing post-surgery. to address these issues, we placed a stent in the reconstructed urethra of adolescents with hypospadias and performed urethral irrigation postoperatively.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with hypospadias and in tanner stages ii-v at the department of urology, affiliated children's hospital of chongqing medical university. 2. patients and their guardians have been informed about the nature of the study, understand the protocol, can ensure compliance, and have signed an informed consent form. exclusion criteria: 1. patients undergoing meatal advancement and glanuloplasty (magpi) only. 2. patients undergoing penile recurvature correction only. 3. patients undergoing urethrostomy only. 4. patients with contraindications to the procedure, such as severe cardiac disease, systemic or localized infection, thrombocytopenia, coagulation disorders, congenital immunodeficiencies, or uncontrolled diabetes mellitus. 5. patients already enrolled in or during the follow-up of other clinical studies. patients who do not wish to participate in this study or demonstrate poor compliance with follow-up requirements.
postoperative adjuvant immunotherapy for hepatocellular carcinoma: risk factor analysis and prognostic modelling

Conditions: Hepatocellular Carcinoma; Adjuvant Immunotherapy; Checkpoint Inhibitor

Summary: the aim of this study was to analyse the independent risk factors for hepatocellular carcinoma (hcc) patients undergoing adjuvant immunotherapy after liver resection surgery, and to develop a prognostic model based on these factors.

by retrospectively collecting patient data from a single centre of liver surgery at tongji hospital between february 2019 and february 2023, the study aimed to comprehensively evaluate patients' demographic characteristics, oncological parameters, surgical details and response to immunotherapy to identify the key factors affecting postoperative recurrence and survival.

Eligibility criteria:
inclusion criteria: * hcc confirmed by pathologists * undergone a curative resection (r0) * aged 18-75 years * no previous systematic treatment and locoregional therapy for hcc prior to randomization * absence of major macrovascular invasion * no extrahepatic spread exclusion criteria: * known fibrolamellar hcc, sarcomatoid hcc, mixed cholangiocarcinoma or recurrent hcc * any preoperative treatment for hcc including local and systemic therapy * unable to receive adjuvant therapy due to surgery-related complications, acute active infectious diseases, active or history of autoimmune disease, or immune deficiency * incomplete clinical data
cancer biology of retinoblastoma

Conditions: Retinoblastoma

Summary: many children with the childhood cancer, retinoblastoma, have surgery to remove the tumor and sometimes the entire eye. the purpose of this study is to collect the extra tissue from patients who undergo tumor removal for laboratory experiments that will help us understand not only what occurs in retinoblastoma cells but also how cells normally function. some of these studies will include an evaluation of how cells control the way that genes are expressed, how cells "know" to become retinal cells, how cells remain retinal cells, how cells lose their identity as retinal cells, what changes make retinoblastoma cells different from normal retinal cells, and what changes make some retinoblastomas worse than others.


Eligibility criteria:
inclusion criteria: * patient must have retinoblastoma * patient must be receiving biopsy, partial surgical excision of the tumor, complete excision of the tumor, or enucleation of the eye as part of their standard care. * parental consent exclusion criteria: * diagnosis other than retinoblastoma * no surgical sampling of tumor is planned as part of standard care * parental preference to not participate.

Keywords: retinoblastoma
transjugular intrahepatic portosystemic shunts improve survival in patients with cirrhosis and recurrent ascites

Conditions: Refractory Ascites

Summary: currently, there is limited evidence regarding the survival benefit of early transjugular intrahepatic portal shunt (tips) placement in patients with cirrhosis and recurrent ascites. this observational study aimed to assess whether early tips improves the survival of patients with advanced cirrhosis and recurrent ascites. we will compare large volume paracenteses plus albumin (lvp+a） to see if tips improves the survival of patients with advanced cirrhosis and recurrent ascites.


Eligibility criteria:
inclusion criteria: definite diagnosis of recurrent ascites in cirrhosis (based on clinical symptoms, laboratory and imaging studies, or liver biopsy) tips or lvp+a therapy, - exclusion criteria: malignant neoplasm, including hepatocellular carcinoma with extrahepatic metastasis prior liver transplantation severe heart and lung dysfunction recurrent hepatic encephalopathy concomitant active infection tips with the use of uncovered stents complete portal vein thrombosis -
the secondary prevention trial for ischemic stroke with dengzhanshengmai capsule

Conditions: Stroke

Summary: in order to observe the secondary preventive effect of the dengzhanshengmai capsule on ischemic stroke, the investigators hold the large randomized control trial (rct). 3143 subjects are included in 83 clinical research centers all over china. the subjects are randomly grouped into two groups. the basic therapy included antiplatelet aggregation, stroke health education, management of blood pressure, blood lipid and blood glucose, etc. the treating group will take the compound chinese medicine deng zhan sheng mai capsule and the contrast group will take the placebo for twelve months. then all of the subjects are visited on the 30th, 90th, 180th, 360th day after inclusion. the recurrence of stroke, cardiovascular events, and peripheral arterial events are observed.

objective:to observe the secondary clinical effect of the deng zhan sheng mai capsule on ischemic stroke patients. methods:3143 subjects suffering from acute ischemic stroke are included in 83 clinical research centers all over china. the subjects are randomly divided into two groups:the treating group and the placebo group.both groups accept the basic therapy and test drug.the basic therapy included antiplatelet aggregation,stroke health education,management of blood pressure,blood lipid and blood glucose,etc.the patients in dengzhan shengmaigroup take deng zhan sheng mai capsule and the placebo group take the placebo drug for twelve months.then all of the subjects are visited on the 30th,90th,180th,360th day after inclusion. primary endpoints(cerebral infarction,intracerebral hemorrhage,subarachnoid hemorrhage) and secondary endpoints(cardiovascular events,peripheral arterial disease),functional disability are observed at each follow up.

Eligibility criteria:
inclusion criteria: * 40-75 years old * ischemic stroke diagnosed by ct/mri scan * patient presenting from 14 days to 6 months of first onset of ischemic stroke * presence of at least one risk factor of stroke (such as hypertension, diabetes mellitus, coronary heart disease, hyperlipidemia, and smoking, etc.) that can be interfered in * informed consent exclusion criteria: * silent cerebral infarction * cerebral infarction due to other causes except artery scleroses (i.e. cardiogenic embolism, hypercoagulable state, endangium stripping, vasculitis) * presence of serious heart disease, heart, liver, lung, and kidney functional failure; malignancy; alimentary tract hemorrhage mental disorder and noncooperation with physician * females during pregnancy or lactation * already attend other clinical trial

Keywords: recurrence of stroke dengzhan shengmai capsule traditional chinese medicine
comparison of record in veriton camera to the anger camera procedure in patients treated by 131-iodine

Conditions: Device

Summary: the aim of this study is to show that the spect/ct whole body recording procedure lasting less than or equal to 30 minutes in a veriton-ct™ camera, can be substituted for the classic procedure, giving at least equivalent information in searches for primary or metastatic neoplastic lesions.

patients with thyroid cancer treated with iodine 131 will receive an iodine 131 activity of between 1100 and 3700 mbq delivered as a capsule orally to eliminate the remaining thyroid tissue. hormone replacement therapy (hrt) is then started to correct the hypothyroidism. 3 days later, a 2d whole body recording will be associated with complementary single photonic emission computed tomography ct scans (spect/ct). it enables visualising the fixation of iodine 131, provides information on the thyroid remnants left in place during surgical thyroidectomy and to carry out an extension assessment by visualizing the possible presence of metastases fixing iodine at the level of the regional lymph nodes or many distant sites, in particular, lung and bone. in vericath study, the hypothesis is that this classic procedure could be advantageously replaced by a single full-body spect/ct recording of a limited duration (≤ 30 minutes), obtained with a camera state-of-the-art semiconductor device called the veriton-ct™ (spectrum dynamics medical) camera.

Eligibility criteria:
inclusion criteria: 1. patients over the age of 18, who have understood and signed the informed consent form. 2. person suffering from thyroid cancer and for whom the multidisciplinary meeting has validated a treatment by iodine 131 (1100 mbq or 3700 mbq). 3. person with no contraindication to carrying out the examination. 4. person affiliated to a social security scheme. exclusion criteria: 1. person with a known allergy to one of the components of the radiopharmaceutical (iodine 131 capsule). 2. pregnant woman or woman of childbearing age and without suitable contraceptive means, or breastfeeding mother. 3. person whose medical condition is unstable and/or unable to remain still in the supine position during recordings. 4. person deprived of liberty by a judicial or administrative decision. 5. person of full age subject to a measure of legal protection (guardianship, curators, safeguard of justice). 6. adult person unable to express his consent and who is not the subject of a legal protection measure.

Keywords: iodine 131 thyroid cancer camera czt (cadmium-zinc-tellurid)
comparison of disposcope endoscope and fiberoptic bronchoscope

Conditions: Therapeutic Procedural Complication

Summary: the fiberoptic bronchoscope (fob) has been the preferred instrument for many years in the management of difficult tracheal intubation, and it is considered as a gold standard. the disposcope endoscope (de) is a medical device for endotracheal intubation used in clinical practice recently.this study compares fob and de for awake orotracheal intubation in obese patients with anticipated difficult airway.

forty obese patients with anticipated difficult airways were randomised to undergo awake orotracheal intubation by fob(group f) or de(group d) after conscious sedation. the conditions of orotracheal intubation, the time needed to view the vocal cords and to complete the orotracheal intubation, the hemodynamic changes and the adverse events including bradycardia, respiratory depression during orotracheal intubation, throat pain, hoarseness and memory after surgery were recorded. the ease of view the vocal cords and passing the tracheal tube through the glottis were also evaluated by using a visual analogue scale (vas) by operator.

Eligibility criteria:
inclusion criteria: * asa classifications of i-ii, modified mallampati classification of 3 or 4, requiring general anesthesia were included. exclusion criteria: * exclusion criteria included age younger than 18 yr, * asa class iv or v, * abnormalities of the heart, brain, liver, lung, kidney and coagulation functions

Keywords: fiberoptic bronchoscope disposcope endoscope awake orotracheal intubation
urokinase versus primary video-assisted thorascopic surgery for empyema

Conditions: Empyema

Summary: this study will compare vats versus chest drain insertion and urokinase in the treatment of childhood empema by a randomised prospective study.


Eligibility criteria:
inclusion criteria: * patients under the age of 16 referred to gosh for management of empyema exclusion criteria: -
effect of physiotherapy in stroke

Conditions: Stroke

Summary: the study was aimed to determine the volumetric change in the corpus callosum after the rehabilitation program in patients with stroke. a total of 42 patients (22 males, 20 females), 21 right hemiplegic and 21 left hemiplegic patients with unilateral hemiplegia were enrolled in the rehabilitation program. traditional physiotherapy treatment was applied 5 days in a week, 1 hour in a day for 6 weeks. the corpus callosum volumes were measured and evaluated on magnetic resonance imaging (mri) images before and after the treatment.

physical therapy after stroke contributes to the physical and social recovery of the paralyzed person. corpus callosum is the commissural fibers consisting of white matter connecting the cortical areas between hemispheres. its main function is to provide information exchange and coordination by establishing interhemispheric connections between areas in the right and left hemispheres. inactivity and decreased physical activity may cause a decrease in the volume of the corpus callosum in patients with stroke. it was aimed to determine the volumetric change in the corpus callosum after the rehabilitation program in patients with stroke. a total of 42 patients (22 males, 20 females), 21 right hemiplegic and 21 left hemiplegic patients with unilateral hemiplegia were enrolled in the rehabilitation program. traditional physiotherapy treatment was applied 5 days in a week, 1 hour in a day for 6 weeks. the corpus callosum volumes were measured and evaluated on magnetic resonance imaging (mri) images before and after the treatment.

Eligibility criteria:
inclusion criteria: * patients diagnosed with stroke * patients had unilateral hemiplegia * patients practiced a rehabilitation program at the physical medicine and rehabilitation exclusion criteria: * patients had other neurological disease * patients had mental disorders

Keywords: corpus callosum hemiplegia physiotherapy stroke
freeze-dried plasma in the initial management of coagulopathy in trauma patients

Conditions: Trauma; Coagulopathy

Summary: knowledge and management of bleeding in severe trauma has changed. a specific coagulopathy is present in 40% of cases. it has a very early onset and this coagulopathy is associated with increased mortality. it must be detected and treated early, as illustrated by the military medical data, from the iraq war and civilian medicine. however, fresh frozen plasma (ffp) requires a thawing step.the french army has encouraged the development of a freeze-dried plasma of innovative because viral inactivation and universal blood grouping, well tolerated, with a reduced risk of trali. this sophisticated therapeutic product can be administered after 6 minutes of reconstitution without the need for cross-matching. nevertheless, its used is currently reserved for military purpose in overseas operations and needs to be evaluated for civil use. to this end, the investigators need to evaluate the impact on coagulopathy of an immediate availability of plasma.


Eligibility criteria:
inclusion criteria: * emergency * trauma patient admitted in participating trauma care centers * severe bleeding requiring transfusion with 4 units of red blood cells and 4 emergency plasma. * inclusion performed within the first 6 hours after trauma. exclusion criteria: * patient taking anticoagulants * patients who have received hemostatic treatment during transport (tranexamic -acid excluded) * minor patient * pregnant or breastfeeding women
radiation therapy with or without bicalutamide and goserelin in treating patients with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: radiation therapy uses high-energy x-rays to damage tumor cells. bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone. it is not yet known if radiation therapy is more effective with or without bicalutamide and goserelin in treating prostate cancer. purpose: randomized phase iii trial to compare the effectiveness of radiation therapy with or without bicalutamide and goserelin in treating patients who have localized prostate cancer.

objectives: * compare the potential beneficial impact of radiotherapy with or without adjuvant bicalutamide and goserelin on the long-term outcome of patients with localized prostate cancer. * compare the acute and late radiation-induced side effects of these regimens in these patients. * compare the biochemical/clinical disease-free survival, overall survival, and time to local progression in patients treated with these regimens. * compare the time to clinical biological failure or death in patients treated with these regimens. * compare the quality of life of patients treated with these regimens. outline: this is a randomized, multicenter study. patients are stratified according to tumor class (t1b-c vs t2a), initial prostate-specific antigen level (10 ng/ml vs 10-20 ng/ml vs greater than 20 ng/ml), gleason score (2-6 vs 7-10) and participating center. patients are randomized to 1 of 2 treatment arms. * arm i: patients undergo 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for 7-7.5 weeks. * arm ii: patients receive adjuvant oral bicalutamide once daily on days 1-30 and goserelin subcutaneously on days 8 and 98. beginning on day 8, patients undergo radiotherapy as in arm i. quality of life is assessed at baseline and then at months 6, 12, 24, and 36. patients are followed every 6 months for 5 years and then annually thereafter. projected accrual: a total of 800 patients (400 per treatment arm) will be accrued for this study within 5 years.

Eligibility criteria:
disease characteristics: * histologically confirmed stage ii prostate cancer * t1b-c, n0, m0 with prostate-specific antigen (psa) at least 10 ng/ml and/or gleason score at least 7 (uicc 1997 classification) or * t2a, n0, m0 (uicc 1997 classification) * serum psa no greater than 50 ng/ml * no involvement of pelvic lymph nodes patient characteristics: age: * 80 and under performance status: * who 0-2 life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * no other malignancy within the past 5 years except adequately treated basal cell skin cancer * no psychological, familial, sociological, or geographical condition that would preclude study participation prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * no prior hormonal therapy radiotherapy: * no prior pelvic radiotherapy surgery: * no prior radical prostatectomy

Keywords: stage iib prostate cancer stage iia prostate cancer